- Home
- MDT
MDT
Medtronic plc.
as 12-20-2024 4:00pm EST
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
| Founded: | 1949 | Country: | Ireland |
| Employees: | N/A | City: | GALWAY |
| Market Cap: | 110.6B | IPO Year: | N/A |
| Target Price: | $93.67 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 3.27 | EPS Growth: | 6.04 |
| 52 Week Low/High: | $75.96 - $92.68 | Next Earning Date: | 02-18-2025 |
| Revenue: | $32,996,000,000 | Revenue Growth: | 3.25% |
| Revenue Growth (this year): | 4.76% | Revenue Growth (next year): | 4.60% |
Latest Medtronic plc. News
MDT Breaking Stock News: Dive into MDT Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Jim Cramer: Is Medtronic’s (MDT) Deep Discount a Steal?
Zacks
2 days ago
Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?
TipRanks
3 days ago
Medtronic price target lowered to $89 from $93 at Truist
MT Newswires
3 days ago
Baird Adjusts Medtronic Price Target to $90 From $93, Maintains Neutral Rating
Zacks
4 days ago
BSX Trades Near 52-Week High: Does the Stock Hold More Potential?
Insider Monkey
6 days ago
Should You Invest in Medtronic (MDT)?
MedTech Dive
6 days ago
PFA to surpass radiofrequency ablation in 2025: Citi survey
MT Newswires
6 days ago
Goldman Sachs Adjusts Price Target on Medtronic to $83 From $84, Maintains Sell Rating
Compare MDT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDT Medtronic plc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.